Cancer – Page 6

Targeting multiple myeloma with BCMA-CAR NK cells expressing a GPRC5D-NKG2D bispecific antibody

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate s15.BsAb.BCMA-CAR NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with multiple myeloma Mechanism of Action s15.BsAb.BCMA-CAR NK cells are umbilical cord…

Novel T cell receptor-STEM T cell immunotherapy in lung cancer

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate HLA-A*02 restricted CT83 antigen-specific T cell receptor-engineered T cell cells (CT83TCR-STEM T cells for short). Area of Impact Metastatic lung cancer patients who fail to respond to immune…

Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate EGFR-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with metastatic breast cancer, especially HER2-low breast cancer Mechanism of Action EGFR-CAR_sIL15…

Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate EGFR-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with metastatic breast cancer, especially HER2-low breast cancer Mechanism of Action EGFR-CAR_sIL15…

Overcoming resistance to standard CD19-targeted CAR T using a novel triple antigen targeted vector

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate A tri-specific chimeric antigen receptor (CAR) T cell product that will prevent relapse since targets 3 different tumor antigens Area of Impact Relapse associated with single or double…

Next generation affinity-tuned CAR for prostate cancer

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate A next generation cell therapy product that targets prostate cancer cells Area of Impact Prostate cancer Mechanism of Action The therapeutic candidate when expressed on the surface of…

CD72 nanoCARs for the treatment of refractory pediatric B-cell acute lymphoblastic leukemia

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate CD72-targeting chimeric antigen receptor (CAR) T cells incorporating fully synthetic nanobodies Area of Impact Pediatric B-cell acute lymphoblastic leukemia refractory to currently available treatments without other potentially curative…

Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Area of Impact Glioblastoma is the most common malignant brain tumor, affecting approximately…

CAR-Tnm cell therapy for melanoma targeting TYRP-1

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate Autologous naive/memory progenitor T cells genetically modified to express a chimeric antigen receptor targeting the Tyrosinase-related protein 1 Area of Impact Patient with melanoma, without response or with…

HSC-Engineered Off-The-Shelf CAR-iNKT Cell Therapy for Multiple Myeloma

Post author:
Post published:April 30, 2025
Post category:

Translational Candidate stem cell-based off-the-shelf CAR-iNKT cells Area of Impact multiple myeloma (MM) Mechanism of Action The proposed therapeutic candidate can directly kill MM tumor cells. Unmet Medical Need MM…

Subscribe to Receive CIRM News